UNSPSC 51333506: Pridinol

This classification denotes an antipsychotic agent with the molecular formula C20H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E75Q6SUUB, chemically known as 1,1-diphenyl-3-piperidino-1-propanol but generally known as pridinol, which bears US NIH Compound Identifier 4904. European Medicines Agency schedules Pridinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10037MIG.

UNSPSC 51333506 Pridinol is a Commodity code that state and local governments use to classify pharmaceutical products, though recent solicitations show procurement activity spanning naloxone, safe drug deactivation systems, generic pharmaceuticals, and over-the-counter products rather than pridinol specifically. The code captures purchases of prescription medications, OTC drugs, and related delivery systems procured by health departments, county health systems, and state agencies to support community health, emergency response, and pharmacy benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances administering contracts across dozens of participating jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities in Minnesota and Oregon). The Minnesota cooperative has emerged as a standout repeat vehicle, consolidating pharmaceutical procurement across multiple state and local partners through a single RFP cycle.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs operating outside traditional pharmacy benefit manager and group purchasing organization channels, marking an exploratory phase before formal RFP issuance. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 on January 20, 2026, seeking generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co.), with proposals due March 26, 2026, and awarded products effective July 1, 2026; evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and administrative fee agreement. Vendors must hold cGMP certification, comply with the Drug Supply Chain Security Act, and maintain relationships with at least two of the three authorized wholesalers.